References
1. https://www.worldometers.info/coronavirus/., August 17, 2021
2. Tabarsi, P., S. Barati, H. Jamaati, S. Haseli, M. Marjani, A. Moniri, et al., Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. International immunopharmacology, 2021. 90 : p. 107205.
3. Mohtadi, N., A. Ghaysouri, S. Shirazi, E. Shafiee, E. Bastani, T. Kokhazadeh, et al., Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series. Virology, 2020. 548 : p. 1-5.
4. Kaveri, S., M. Maddur, P. Hegde, S. Lacroix‐Desmazes, and J. Bayry,Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clinical & Experimental Immunology, 2011.164 : p. 2-5.
5. Ferrara, G., A. Zumla, and M. Maeurer, Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.The American journal of medicine, 2012. 125 (10): p. 1036. e1-1036. e8.
6. Liu, X., W. Cao, and T. Li, High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Frontiers in immunology, 2020.11 : p. 1660.
7. Kanjilal, S. and M.J. Mina, Passive immunity for the treatment of influenza: quality not quantity. The Lancet Respiratory Medicine, 2019. 7 (11): p. 922-923.
8. Nimmerjahn, F. and J.V. Ravetch, Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol., 2008. 26 : p. 513-533.
9. Xie, Y., S. Cao, H. Dong, Q. Li, E. Chen, W. Zhang, et al.,Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. The Journal of infection, 2020. 81 (2): p. 318.
10. Liu, J., Y. Chen, R. Li, Z. Wu, Q. Xu, Z. Li, et al.,Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multi-center study. Clinical Microbiology and Infection, 2021.
11. Shao, Z., Y. Feng, L. Zhong, Q. Xie, M. Lei, Z. Liu, et al.,Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study. Clinical & translational immunology, 2020. 9 (10): p. e1192.
12. Farrokhpour, M., N. Rezaie, N. Moradi, F.G. Rad, S. Izadi, M. Azimi, et al., Infliximab and intravenous Gammaglobulin in hospitalized severe COVID-19 patients in intensive care unit. Archives of Iranian medicine, 2021. 24 (2): p. 139-143.
13. Gharebaghi, N., R. Nejadrahim, S.J. Mousavi, S.-R. Sadat-Ebrahimi, and R. Hajizadeh, The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC infectious diseases, 2020. 20 (1): p. 1-8.
14. Herth, F.J., G. Sakoulas, and F. Haddad, Use of intravenous immunoglobulin (Prevagen or Octagam) for the treatment of COVID-19: retrospective case series. Respiration, 2020. 99 (12): p. 1145-1153.
15. Pourahmad, R., B. Moazzami, and N. Rezaei, Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19. SN Comprehensive Clinical Medicine, 2020: p. 1-5.